Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

ALLOCATIONS OUT: American Medical Systems Europe B.V. €4.25bn 6-part Sr Unsec; 3mE+63 & MS+53 & MS+75 & MS+110 & MS+135 & MS+170

IGC European Market: Deal Flow - General

Issuer

Term

Maturity

Size

Ranking

Type

IPT

Spread Set

ISIN

American Medical Systems Europe B.V.

2yr

01-Dec-28

€500m

Sr Unsec

Floating

3mE+85/90

3mE+63

XS3577499059

American Medical Systems Europe B.V.

2yr

01-Dec-28

€500m

Sr Unsec

Fixed

MS+75/80

MS+53

XS3573007385

American Medical Systems Europe B.V.

4yr

01-Dec-30

€750m

Sr Unsec

Fixed

MS+105a

MS+75

XS3573008607

American Medical Systems Europe B.V.

8yr

01-Dec-34

€750m

Sr Unsec

Fixed

MS+135/140

MS+110

XS3573008862

American Medical Systems Europe B.V.

12yr

01-Dec-38

€1bn

Sr Unsec

Fixed

MS+160/165

MS+135

XS3573009167

American Medical Systems Europe B.V.

20yr

01-Dec-46

€750m

Sr Unsec

Fixed

MS+200a

MS+170

XS3573009670


Tranche 1 (2yr FRN): Final Books >€1.4bn. Peak book >€1.4bn
Tranche 2 (2yr FXD): Final Books >€1.6bn. Peak book greater than €1.8bn. Benchmark: OBL 2.4 Oct-28 #188 (HR 105%)
Tranche 3 (4yr): Final Books >€2.2bn. Peak book greater than €2.9bn. Benchmark: OBL 2.2 Oct-30 #192 (HR 103%)
Tranche 4 (8yr): Final Books >€2.5bn. Peak book greater than €3.2bn. Benchmark: DBR 2.6 Aug-34 (HR 101%)
Tranche 5 (12yr): Final Books >€2.6bn. Peak book greater than €3.1bn. Benchmark: DBR 1 May-38 (HR 112%)
Tranche 6 (20yr): Final Books >€1.7bn. Peak book greater than €2.7bn. Benchmark: DBR 2 ½ Aug-46 (HR 100%)

Hedge Deadline: 15:45 UKT / 16:45 CET

Launched:
2yr FRN: €500m @ 3mE+63bp - Books greater than €1.3bn
2yr: €500m @ MS+53bp - Books greater than €1.8bn
4yr: €750m @ MS+75bp - Books greater than €2.9bn
8yr: €750m @ MS+110bp - Books greater than €3.2bn
12yr: €1bn @ MS+135bp - Books greater than €3.1bn
20yr: €750m @ MS+170bp - Books greater than €2.7bn
(Combined Books in excess of €15bn)
IPTs: 2yr FRN: 3mE+85/90bp 2yr: MS+75/80bp 4yr: MS+105a 8yr: MS+135/140bp 12yr: MS+160/165bp 20yr: MS+200a


  • Issuer: American Medical Systems Europe B.V. (Country: NL)
  • Guarantor: Boston Scientific Corporation (Ticker: BSX; Country: US)
  • LEI:
    • Issuer: 549300AA2JE6ZQ5D2493
    • Guarantor: Y6ZDD9FP4P8JSSJMW954
  • Guarantor Ratings: A3 (Negative) by Moody's / A- (Negative) by S&P / A- (Stable) by Fitch
  • Expected Issue Ratings: A3 by Moody's / A- by S&P / A- by Fitch
  • Format: SEC Registered, Senior, Unsecured
  • Settlement: 01-Dec-26 (T+8)
  • Size:
    • 2yr FRN: €500m
    • 2yr: €500m
    • 4yr: €750m
    • 8yr: €750m
    • 12yr: €1bn
    • 20yr: €750m
  • Maturity:
    • 2yr FRN: 01-Dec-28
    • 2yr: 01-Dec-28
    • 4yr: 01-Dec-30
    • 8yr: 01-Dec-34
    • 12yr: 01-Dec-38
    • 20yr: 01-Dec-46
  • Final Terms:
    • 2yr FRN: €500m @ 3mE+63#
    • 2yr: €500m @ MS+53#
    • 4yr: €750m @ MS+75#
    • 8yr: €750m @ MS+110#
    • 12yr: €1bn @ MS+135#
    • 20yr: €750m @ MS+170#
  • Coupon:
    • 2yr FRN: 3mE+spread, Qtrly, Act/360
    • 2yr: Fixed, Ann, Act/Act (ICMA)
    • 4yr: Fixed, Ann, Act/Act (ICMA)
    • 8yr: Fixed, Ann, Act/Act (ICMA)
    • 12yr: Fixed, Ann, Act/Act (ICMA)
    • 20yr: Fixed, Ann, Act/Act (ICMA)
  • MWC:
    • 2yr: B+[ ]
    • 4yr: B+[ ]
    • 8yr: B+[ ]
    • 12yr: B+[ ]
    • 20yr: B+[ ]
  • Par Call:
    • 4yr: 1-month
    • 8yr: 3-month
    • 12yr: 3-month
    • 20yr: 6-month
  • Special Mandatory Redemption:
    • 2yr, 4yr, 8yr, 12yr, 20yr: 101% plus accrued interest if the Penumbra Acquisition is not completed by the Special Mandatory Redemption End Date (later of 14-Jan-27, extendable to no later than 14-Jan-28, or five business days after any later agreed Outside Date) or if Boston Scientific will not pursue the acquisition. Proceeds not escrowed
  • B&D: Citigroup
  • Docs: Euronext Dublin GEM Listing / Netherlands (Issuer) & U.S. Law (Guarantor) / €100k and integral multiples of €1k in excess thereof / Tax Call / CoC
  • Clearing: Clearstream Banking S.A. ("Clearstream") and Euroclear Bank SA/NV ("Euroclear")
  • Denominations: €100k and integral multiples of €1k in excess thereof
  • Selling Restrictions: As per Preliminary Prospectus Supplement. Sales to Canada via exemption.
  • UoP: We intend to use the net proceeds from this offering, together with any net proceeds of the USD Notes offering, short-term borrowings and/or borrowings under our credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Penumbra Acquisition and to pay related fees and expenses and, to the extent that the net proceeds from this offering are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.
  • Stabilization: Relevant stabilization regulations including FCA/ICMA apply.
  • Target Market: MiFID II and UK MiFIR - professionals/ECPs-only / No EEA PRIIPs key information document (KID) or UK disclosure document required by DISC – Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No EEA PRIIPs KID or UK DISC disclosure document has been prepared as the notes are not available to retail investors in the European Economic Area or the UK.
  • Active Bookrunners: Barclays, Citigroup, and J.P. Morgan
  • Books Subject: 12:45 UKT / 13:45 CET
  • Timing: Today's business (Allocations & pricing this PM)
  • Advertisement: Any offering of securities will be made only by means of a prospectus supplement, which will be filed with the SEC, and accompanying prospectus. In the event that the company proceeds with an offering, you may obtain a copy of the prospectus supplement for free by visiting EDGAR on the SEC website athttps://clicktime.symantec.com/3A2gL34bxV7t6bDgb9gYS6K7GS?u= www.sec.gov [sec.gov]. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it.
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.